Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in
children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with
irritability, agitation, or self-injurious behaviors to study the efficacy and safety of
pimavanserin